No. That is right when there's a pandemic emergency. We're a gap-filler in terms of making sure that there is production capacity if it's required for cell-based biologics.
Separate from that, in non-pandemic periods, we'll be focusing on pandemic preparedness, but we'll also be focusing on other production biologics such as infectious diseases and orphan drugs for rare diseases. We will collaborate with the private sector with that, because the key thing that's one element in terms of the mandate is that this is an example of how we will help to increase the biometric capacity of the private sector.
In such cases, for example, we will work with SMEs that in some instances today have limited access to be able to scale up in a facility of this nature. That's an example of where we will bring them in to support the capacity.
What I want to confirm is that in every respect of the mandate, we will always be collaborating with the biomanufacturing sector, but the key priority will be that we will have our facility on a constant readiness state to be able to pivot to respond to pandemic emergencies in collaboration with the private sector and academia.